Advertisement
Screener

Kyverna Therapeutics, Inc. (KYTX) Material Contracts

Kyverna Therapeutics, Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-08-11: Form 10-Q; Exhibit 10.4; Description First Amendment to Loan and Security Agreement, entered into as of July 8, 2026 and made effective as of June 30, 2026, by and among Kyverna Therapeutics, Inc., Oxford Finance LLC, as collateral agent, and the lenders named therein or otherwise a party thereto from time to time..
  • 2026-08-11: Form 10-Q; Exhibit 10.1; Description Employment Offer Letter, dated April 13, 2026, between Kyverna Therapeutics, Inc. and Nadia Dac..
  • 2026-05-18: Form 8-K; Exhibit 10.2; Description Letter Agreement, dated May 14, 2026, between Kyverna Therapeutics, Inc. and Marc Grasso..
  • 2026-05-18: Form 8-K; Exhibit 10.1; Description Employment Offer Letter, dated May 8, 2026, between Kyverna Therapeutics, Inc. and Gregory Martini..
FiledFormExhibitDescription
2026-08-1110-Q10.4First Amendment to Loan and Security Agreement, entered into as of July 8, 2026 and made effective as of June 30, 2026, by and among Kyverna Therapeutics, Inc., Oxford Finance LLC, as collateral agent, and the lenders named therein or otherwise a party thereto from time to time.
2026-08-1110-Q10.1Employment Offer Letter, dated April 13, 2026, between Kyverna Therapeutics, Inc. and Nadia Dac.
2026-05-188-K10.2Letter Agreement, dated May 14, 2026, between Kyverna Therapeutics, Inc. and Marc Grasso.
2026-05-188-K10.1Employment Offer Letter, dated May 8, 2026, between Kyverna Therapeutics, Inc. and Gregory Martini.
2026-05-1210-Q10.1Employment Offer Letter, dated January 13, 2026, between Kyverna Therapeutics, Inc. and Mayo Pujols.
2026-03-2610-K10.19Loan and Security Agreement, dated October 31, 2025, among Kyverna Therapeutics, Inc., Oxford Finance LLC, as collateral agent, and the lenders named therein or otherwise a party thereto from time to time.
2026-02-038-K10.1Kyverna Therapeutics, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan.
2026-01-128-K10.1Employment Offer Letter, dated January 9, 2026, between Kyverna Therapeutics, Inc. and Christi Shaw.
2025-06-308-K10.2LETTER AGREEMENT, ENTERED INTO ON JUNE 28, 2025, BETWEEN KYVERNA THERAPEUTICS, INC. AND RYAN JONES
2025-06-308-K10.1EMPLOYMENT OFFER LETTER, DATED JUNE 5, 2025, BETWEEN KYVERNA THERAPEUTICS, INC. AND MARC GRASSO, MD
2025-03-2710-K10.16Kyverna Therapeutics, Inc. Non-Employee Director Compensation Program.
2025-03-2710-K10.8Employment Offer Letter, dated December 30, 2024, between Kyverna Therapeutics, Inc. and Naji H. Gehchan, M.D.
2024-11-268-K10.1Letter Agreement, dated November 20, 2024, between Kyverna Therapeutics, Inc. and James Chung, M.D., Ph.D.
2024-09-168-K10.3KYVERNA THERAPEUTICS, INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN
2024-09-168-K10.2SEPARATION AND GENERAL RELEASE AGREEMENT, DATED SEPTEMBER 13, 2024, BETWEEN KYVERNA THERAPEUTICS, INC. AND PETER MAAG, PH.D
2024-09-168-K10.1EMPLOYMENT OFFER LETTER, DATED SEPTEMBER 14, 2024, BETWEEN KYVERNA THERAPEUTICS, INC. AND WARNER BIDDLE

Similar stocks

Stock NameCountryMarket CapPE Ratio
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Zura Bio Ltd (ZURA)$0.398B-6.56
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Surrozen, Inc./DE (SRZN)United States$0.395B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
AGENUS INC (AGEN)United States$0.383B1.41
Entera Bio Ltd. (ENTX)$0.485B
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65